Recent news surrounding Akebia Therapeutics centers on its ongoing financial performance updates, commercial adoption metrics for its Vafseo treatment, and clinical trial progress. Corporate earnings reports highlighted continued revenue growth associated with Vafseo sales, alongside updates regarding clinical studies such as the VOICE trial evaluating renal disease interventions. Furthermore, the company continues to manage its operational expenses, evaluate strategic partnerships, and navigate regulatory milestones designed to solidify its standing as a commercial-stage biopharmaceutical leader focused on kidney care solutions.